The FDA is currently reviewing Summit's PD-1/VEGF bispecific as part of a chemotherapy combo for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer.

Sanofi’s vaccine sales dipped 2.5% in 2025, with almost all immunization products declining. Nevertheless, CEO Paul Hudson ...

AstraZeneca has risen as one of pharma’s most prolific investors in China, including a $630 million pledge last week for full ...

Roche aims to become a “top three player” in obesity, Teresa Graham, CEO of the group’s Pharma unit, said Thursday during a ...

Cellares, which last year became the first company to receive the FDA's new advanced manufacturing technology designation, ...

More biopharma organizations were actively recruiting at the end of 2025 than 2024, based on the new BioSpace employment ...

Looking for an IT job? From data engineer to information security, check out the BioSpace list of 10 companies hiring life ...

In this episode of Denatured, Jennifer C. Smith-Parker speaks with RTW’s Rod Wong and Stephanie Sirota how shifting JPM deal timing masks record M&A potential; why oncology, obesity, psychedelics, and ...

Roche’s obesity candidate achieves 22.5% weight loss in Phase II; Moderna pulls the plug on late-stage vaccine trials as ...

While Baseline Therapeutics declined to disclose its starting capital, the startup said it will use the funds to push its GLP ...

Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed ...

After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs ...